A practical reference on tetrapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-09. Anything still debated is marked as such rather than presented as settled.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
Laboratory-grade epitalon is typically supplied as a lyophilized powder. Purity is commonly assessed with reverse-phase high-performance liquid chromatography, often paired with mass spectrometry to confirm molecular identity. Amino acid analysis and peptide mapping can provide additional confirmation of sequence. Certificates of analysis for research materials frequently report purity above 95 percent, although the methods behind such figures vary between suppliers. The absence of a pharmacopeial monograph means that no single standardized assay defines the compound, so reported results depend on the analytical protocol chosen.
Storage recommendations center on limiting moisture, heat, and light. The dry powder is generally kept at minus 20 degrees Celsius, and some suppliers recommend minus 80 degrees for long-term archival. Once dissolved, solutions are usually aliquoted and frozen to avoid repeated freeze-thaw cycles, which can promote aggregation or degradation. Aqueous stability depends on pH and concentration, and buffered saline is often preferred over plain water for biological work. Stability data specific to epitalon remain limited, so general peptide-handling practices are applied by analogy rather than from product-specific validation.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and its calculated monoisotopic mass is approximately 390.35 daltons. The compound does not occur naturally as a free peptide; it is produced by solid-phase peptide synthesis. Because it contains two acidic residues and no basic residues, the neutral form carries a net negative charge at physiological pH. This charge profile influences how the peptide behaves in solution and during chromatographic analysis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Synthetic tetrapeptide, four residues |
| Nominal mass | Approximately 390 Da | Free peptide; salt forms differ |
| Appearance | White to off-white powder | Commonly supplied lyophilised |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffer |
| Typical storage | −20 °C, desiccated | Cold packs used during transport |
Residue composition is the property that most cleanly separates verified material from mislabelled samples. Alanine, glutamate, aspartate and glycine appear in that order from the N-terminus, and the two acidic residues sit in the middle of the chain. Because the peptide is short, it can be produced by solid-phase synthesis and characterised by mass spectrometry without ambiguity. Any reported sample whose measured mass departs substantially from 390 daltons is a different compound or a degraded mixture rather than epitalon.
Epitalon is a synthetic tetrapeptide whose four residues are alanine, glutamate, aspartate and glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9 and its monoisotopic mass is near 390.35 daltons. The peptide carries two acidic side chains, so it is neutral to negatively charged in most aqueous buffers. Published reference summaries usually list it under both spellings, epitalon and epithalon, and treat the two names as the same material.
Nitro cold brew is a variation of cold brew coffee that adds nitrogen gas to create a smooth texture, delivering the nitrogenated coffee from a nitrogen beer tap system. It was introduced in the early 2010s.
In some cities such as Hong Kong, seawater is extensively used for flushing toilets citywide to conserve freshwater resources. Polluting water may be the biggest single misuse of water; to the extent that a pollutant limits other uses of the water, it becomes a waste of the resource, regardless of benefits to the polluter. Like other types of pollution, this does not enter standard accounting of market costs, being conceived as externalities for which the market cannot account. Thus other people pay the price of water pollution, while the private firms' profits are not redistributed to the local population, victims of this pollution. Pharmaceuticals consumed by humans often end up in the waterways and can have detrimental effects on aquatic life if they bioaccumulate and if they are not biodegradable. Municipal and industrial wastewater are typically treated at wastewater treatment plants. Mitigation of polluted surface runoff is addressed through a variety of prevention and treatment techniques.
=== EC 2.1.1: Methyltransferases === EC 2.1.1.1: nicotinamide N-methyltransferase EC 2.1.1.2: guanidinoacetate N-methyltransferase EC 2.1.1.3: thetin—homocysteine S-methyltransferase EC 2.1.1.4: acetylserotonin O-methyltransferase EC 2.1.1.5: betaine—homocysteine S-methyltransferase EC 2.1.1.6: catechol O-methyltransferase EC 2.1.1.7: nicotinate N-methyltransferase EC 2.1.1.8: histamine N-methyltransferase EC 2.1.1.9: thiol S-methyltransferase EC 2.1.1.10: homocysteine S-methyltransferase EC 2.1.1.11: magnesium protoporphyrin IX methyltransferase EC 2.1.1.12: methionine S-methyltransferase EC 2.1.1.13: methionine synthase EC 2.1.1.14: 5-methyltetrahydropteroyltriglutamate—homocysteine S-methyltransferase EC 2.1.1.15: fatty-acid O-methyltransferase EC 2.1.1.16: methylene-fatty-acyl-phospholipid synthase EC 2.1.1.17: phosphatidylethanolamine N-methyltransferase EC 2.1.1.18: polysaccharide O-methyltransferase EC 2.1.1.19: trimethylsulfonium—tetrahydrofolate N-methyltransferase EC 2.1.1.20: glycine N-methyltransferase EC 2.1.1.21: methylamine—glutamate N-methyltransferase EC 2.1.1.22: carnosine N-methyltransferase EC 2.1.1.23: now covered by EC 2.1.1.124, EC 2.1.1.125 and EC 2.1.1.126 EC 2.1.1.24: now covered by EC 2.1.1.77, EC 2.1.1.80 and EC 2.1.1.100 EC 2.1.1.25: phenol O-methyltransferase EC 2.1.1.26: iodophenol O-methyltransferase EC 2.1.1.27: tyramine N-methyltransferase EC 2.1.1.28: phenylethanolamine N-methyltransferase EC 2.1.1.29: Now covered by EC 2.1.1.202, EC 2.1.1.203 and EC .1.1.204 EC 2.1.1.30: tRNA (purine-2- or -6-)-methyltransferase: Reactions previously described are due to EC 2.1.1.32 EC 2.1.1.31: Now covered by EC 2.1.1.221 and EC 2.1.1.228 EC 2.1.1.32: Now covered by EC 2.1.1.213, EC 2.1.1.214, EC 2.1.1.215 and EC 2.1.1.216 EC 2.1.1.33: tRNA (guanine46-N7)-methyltransferase EC 2.1.1.34: tRNA (guanosine18-2′-O)-methyltransferase EC 2.1.1.35: tRNA (uracil54-C5)-methyltransferase EC 2.1.1.36: Now covered by EC 2.1.1.217, EC 2.1.1.218, EC 2.1.1.219, EC 2.1.1.220 EC 2.1.1.37: DNA (cytosine-5-)-methyltransferase EC 2.1.1.38: O-demethylpuromycin O-methyltransferase EC 2.1.1.39: inositol 3-methyltransferase EC 2.1.1.40: inositol 1-methyltransferase EC 2.1.1.41: sterol 24-C-methyltransferase EC 2.1.1.42: flavone 3′-O-methyltransferase EC 2.1.1.43: Now described by EC 2.1.1.354, EC 2.1.1.355, EC 2.1.1.356, EC 2.1.1.357, EC 2.1.1.358, EC 2.1.1.359, EC 2.1.1.360, EC 2.1.1.361 and EC 2.1.1.362 EC 2.1.1.44: L-histidine Nα-methyltransferase EC 2.1.1.45: thymidylate synthase EC 2.1.1.46: isoflavone 4′-O-methyltransferase EC 2.1.1.47: indolepyruvate C-methyltransferase EC 2.1.1.48: Now covered by EC 2.1.1.181, EC 2.1.1.182, EC 2.1.1.183 and EC 2.1.1.184 EC 2.1.1.49: amine N-methyltransferase EC 2.1.1.50: loganate O-methyltransferase EC 2.1.1.51: Now covered by EC 2.1.1.187 and EC 2.1.1.188 EC 2.1.1.52: Now covered by EC 2.1.1.171, EC 2.1.1.172, EC 2.1.1.173 and EC 2.1.1.174 EC 2.1.1.53: putrescine N-methyltransferase EC 2.1.1.54: deoxycytidylate C-methyltransferase EC 2.1.1.55: tRNA (adenine-N6-)-methyltransferase EC 2.1.1.56: mRNA (guanine-N7)-methyltransferase EC 2.1.1.57: methyltransferase cap1 EC 2.1.1.58: deleted, included in EC 2.1.1.57 EC 2.1.1.59: [cytochrome c]-lysine N-methyltransferase EC 2.1.1.60: calmodulin-lysine N-methyltransferase EC 2.1.1.61: tRNA (5-methylaminomethyl-2-thiouridylate)-methyltransferase EC 2.1.1.62: mRNA (2′-O-methyladenosine-N6-)-methyltransferase EC 2.1.1.63: methylated-DNA—[protein]-cysteine S-methyltransferase EC 2.1.1.64: 3-demethylubiquinol 3-O-methyltransferase EC 2.1.1.65: licodione 2′-O-methyltransferase EC 2.1.1.66: Now covered by EC 2.1.1.230 EC 2.1.1.67: thiopurine S-methyltransferase EC 2.1.1.68: caffeate O-methyltransferase EC 2.1.1.69: 5-hydroxyfuranocoumarin 5-O-methyltransferase EC 2.1.1.70: 8-hydroxyfuranocoumarin 8-O-methyltransferase EC 2.1.1.71: phosphatidyl-N-methylethanolamine N-methyltransferase EC 2.1.1.72: site-specific DNA-methyltransferase (adenine-specific) EC 2.1.1.73: deleted: reaction is that of EC 2.1.1.37, DNA (cytosine-5-)-methyltransferase EC 2.1.1.74: methylenetetrahydrofolate—tRNA-(uracil54-C5)-methyltransferase [NAD(P)H-oxidizing] EC 2.1.1.75: apigenin 4′-O-methyltransferase EC 2.1.1.76: quercetin 3-O-methyltransferase EC 2.1.1.77: protein-L-isoaspartate(D-aspartate) O-methyltransferase EC 2.1.1.78: isoorientin 3′-O-methyltransferase EC 2.1.1.79: cyclopropane-fatty-acyl-phospholipid synthase EC 2.1.1.80: protein-glutamate O-methyltransferase EC 2.1.1.81: deleted, included in EC 2.1.1.49 EC 2.1.1.82: 3-methylquercetin 7-O-methyltransferase EC 2.1.1.83: 3,7-dimethylquercetin 4′-O-methyltransferase EC 2.1.1.84: methylquercetagetin 6-O-methyltransferase EC 2.1.1.85: protein-histidine N-methyltransferase EC 2.1.1.86: Now covered by EC 7.2.1.4 EC 2.1.1.87: pyridine N-methyltransferase EC 2.1.1.88: 8-hydroxyquercetin 8-O-methyltransferase EC 2.1.1.89: tetrahydrocolumbamine 2-O-methyltransferase EC 2.1.1.90: methanol—5-hydroxybenzimidazolylcobamide Co-methyltransferase EC 2.1.1.91: isobutyraldoxime O-methyltransferase EC 2.1.1.92: Now included with EC 2.1.1.69 EC 2.1.1.93: is identical to EC 2.1.1.70, 8-hydroxyfuranocoumarin 8-O-methyltransferase EC 2.1.1.94: tabersonine 16-O-methyltransferase EC 2.1.1.95: tocopherol C-methyltransferase EC 2.1.1.96: thioether S-methyltransferase EC 2.1.1.97: 3-hydroxyanthranilate 4-C-methyltransferase EC 2.1.1.98: diphthine synthase EC 2.1.1.99: 3-hydroxy-16-methoxy-2,3-dihydrotabersonine N-methyltransferase EC 2.1.1.100: protein-S-isoprenylcysteine O-methyltransferase EC 2.1.1.101: macrocin O-methyltransferase EC 2.1.1.102: demethylmacrocin O-methyltransferase EC 2.1.1.103: phosphoethanolamine N-methyltransferase EC 2.1.1.104: caffeoyl-CoA O-methyltransferase EC 2.1.1.105: N-benzoyl-4-hydroxyanthranilate 4-O-methyltransferase EC 2.1.1.106: tryptophan 2-C-methyltransferase EC 2.1.1.107: uroporphyrinogen-III C-methyltransferase EC 2.1.1.108: 6-hydroxymellein O-methyltransferase EC 2.1.1.109: demethylsterigmatocystin 6-O-methyltransferase EC 2.1.1.110: sterigmatocystin 8-O-methyltransferase EC 2.1.1.111: anthranilate N-methyltransferase EC 2.1.1.112: glucuronoxylan 4-O-methyltransferase EC 2.1.1.113: site-specific DNA-methyltransferase (cytosine-N4-specific) EC 2.1.1.114: polyprenyldihydroxybenzoate methyltransferase EC 2.1.1.115: (RS)-1-benzyl-1,2,3,4-tetrahydroisoquinoline N-methyltransferase EC 2.1.1.116: 3′-hydroxy-N-methyl-(S)-coclaurine 4′-O-methyltransferase EC 2.1.1.117: (S)-scoulerine 9-O-methyltransferase EC 2.1.1.118: columbamine O-methyltransferase EC 2.1.1.119: 10-hydroxydihydrosanguinarine 10-O-methyltransferase EC 2.1.1.120: 12-hydroxydihydrochelirubine 12-O-methyltransferase EC 2.1.1.121: 6-O-methylnorlaudanosoline 5′-O-methyltransferase EC 2.1.1.122: (S)-tetrahydroprotoberberine N-methyltransferase EC 2.1.1.123: [cytochrome-c]-methionine S-methyltransferase EC 2.1.1.124: Now covered by EC 2.1.1.319, EC 2.1.1.320, EC 2.1.1.321 and EC 2.1.1.322 EC 2.1.1.125: Now covered by EC 2.1.1.319, EC 2.1.1.320 and EC 2.1.1.321 EC 2.1.1.126: Now covered by EC 2.1.1.319, EC 2.1.1.320 and EC 2.1.1.321 EC 2.1.1.127: [ribulose-bisphosphate carboxylase]-lysine N-methyltransferase EC 2.1.1.128: (RS)-norcoclaurine 6-O-methyltransferase EC 2.1.1.129: inositol 4-methyltransferase EC 2.1.1.130: precorrin-2 C20-methyltransferase EC 2.1.1.131: precorrin-2 C17-methyltransferase EC 2.1.1.132: precorrin-6B C5,15-methyltransferase (decarboxylating) EC 2.1.1.133: precorrin-4 C11-methyltransferase EC 2.1.1.134: now with EC 2.1.1.129 EC 2.1.1.135: now EC 1.16.1.8 EC 2.1.1.136: chlorophenol O-methyltransferase EC 2.1.1.137: arsenite methyltransferase EC 2.1.1.138: deleted: Reaction due to EC 2.1.1.137 EC 2.1.1.139: 3′-demethylstaurosporine O-methyltransferase EC 2.1.1.140: (S)-coclaurine-N-methyltransferase EC 2.1.1.141: jasmonate O-methyltransferase EC 2.1.1.142: cycloartenol 24-C-methyltransferase EC 2.1.1.143: 24-methylenesterol C-methyltransferase EC 2.1.1.144: trans-aconitate 2-methyltransferase EC 2.1.1.145: trans-aconitate 3-methyltransferase EC 2.1.1.146: (iso)eugenol O-methyltransferase EC 2.1.1.147: corydaline synthase EC 2.1.1.148: thymidylate synthase (FAD) EC 2.1.1.149: Now covered by EC 2.1.1.267, flavonoid 3′,5′-methyltransferase EC 2.1.1.150: isoflavone 7-O-methyltransferase EC 2.1.1.151: cobalt-factor II C20-methyltransferase EC 2.1.1.152: precorrin-6A synthase (deacetylating) EC 2.1.1.153: vitexin 2′′-O-rhamnoside 7-O-methyltransferase EC 2.1.1.154: isoliquiritigenin 2′-O-methyltransferase EC 2.1.1.155: kaempferol 4′-O-methyltransferase EC 2.1.1.156: glycine/sarcosine N-methyltransferase EC 2.1.1.157: sarcosine/dimethylglycine N-methyltransferase EC 2.1.1.158: 7-methylxanthosine synthase EC 2.1.1.159: theobromine synthase EC 2.1.1.160: caffeine synthase EC 2.1.1.161: dimethylglycine N-methyltransferase EC 2.1.1.162: glycine/sarcosine/dimethylglycine N-methyltransferase EC 2.1.1.163: demethylmenaquinone methyltransferase EC 2.1.1.164: demethylrebeccamycin-D-glucose O-methyltransferase EC 2.1.1.165: methyl halide transferase EC 2.1.1.166: 23S rRNA (uridine2552-2′-O)-methyltransferase EC 2.1.1.167: 27S pre-rRNA (guanosine2922-2′-O)-methyltransferase EC 2.1.1.168: 21S rRNA (uridine2791-2′-O)-methyltransferase EC 2.1.1.169: tricetin 3′,4′,5′-O-trimethyltransferase EC 2.1.1.170: 16S rRNA (guanine527-N7)-methyltransferase EC 2.1.1.171: 16S rRNA (guanine966-N2)-methyltransferase EC 2.1.1.172: 16S rRNA (guanine1207-N2))-methyltransferase EC 2.1.1.173: 23S rRNA (guanine2445-N2)-methyltransferase EC 2.1.1.174: 23S rRNA (guanine1835-N2)-methyltransferase EC 2.1.1.175: tricin synthase EC 2.1.1.176: 16S rRNA (cytosine967-C5)-methyltransferase EC 2.1.1.177: 23S rRNA (pseudouridine1915-N3)-methyltransferase EC 2.1.1.178: 16S rRNA (cytosine1407-C5)-methyltransferase EC 2.1.1.179: 16S rRNA (guanine1405-N7)-methyltransferase EC 2.1.1.180: 16S rRNA (adenine1408-N1)-methyltransferase EC 2.1.1.181: 23S rRNA (adenine1618-N6)-methyltransferase EC 2.1.1.182: 16S rRNA (adenine1518-N6/adenineadenine1519-N6)-dimethyltransferase EC 2.1.1.183: 18S rRNA (adenine1779-N6/adenine1780-N6)-dimethyltransferase EC 2.1.1.184: 23S rRNA (adenine2085-N6)-dimethyltransferase EC 2.1.1.185: 23S rRNA (guanosine2251-2′-O)-methyltransferase EC 2.1.1.186: 23S rRNA (cytidine2498-2′-O)-methyltransferase EC 2.1.1.187: 23S rRNA (guanine745-N1)-methyltransferase EC 2.1.1.188: 23S rRNA (guanine748-N1)-methyltransferase EC 2.1.1.189: 23S rRNA (uracil747-C5)-methyltransferase EC 2.1.1.190: 23S rRNA (uracil1939-C5)-methyltransferase EC 2.1.1.191: 23S rRNA (cytosine1962-C5)-methyltransferase EC 2.1.1.192: 23S rRNA (adenine2503-C2)-methyltransferase EC 2.1.1.193: 16S rRNA (uracil1498-N3)-methyltransferase EC 2.1.1.194: A mixture of EC 2.1.1.192 and EC 2.1.1.224 EC 2.1.1.195: cobalt-precorrin-5B (C1)-methyltransferase EC 2.1.1.196: cobalt-precorrin-7 (C15)-methyltransferase (decarboxylating) EC 2.1.1.197: malonyl-[acyl-carrier protein] O-methyltransferase EC 2.1.1.198: 16S rRNA (cytidine1402-2′-O)-methyltransferase EC 2.1.1.199: 16S rRNA (cytosine1402-N4)-methyltransferase EC 2.1.1.200: tRNA (cytidine32/uridine32-2′-O)-methyltransferase EC 2.1.1.201: 2-methoxy-6-polyprenyl-1,4-benzoquinol methylase EC 2.1.1.202: multisite-specific tRNA:(cytosine-C5)-methyltransferase EC 2.1.1.203: tRNA (cytosine34-C5)-methyltransferase EC 2.1.1.204: tRNA (cytosine38-C5)-methyltransferase EC 2.1.1.205: tRNA (cytidine32/guanosine34-2′-O)-methyltransferase EC 2.1.1.206: tRNA (cytidine56-2′-O)-methyltransferase EC 2.1.1.207: tRNA (cytidine34-2′-O)-methyltransferase EC 2.1.1.208: 23S rRNA (uridine2479-2′-O)-methyltransferase EC 2.1.1.209: 23S rRNA (guanine2535-N1)-methyltransferase EC 2.1.1.210: demethylspheroidene O-methyltransferase EC 2.1.1.211: tRNASer(uridine44-2′-O)-methyltransferase EC 2.1.1.212: 2,7,4′-trihydroxyisoflavanone 4′-O-methyltransferase EC 2.1.1.213: tRNA (guanine110-N2)-dimethyltransferase EC 2.1.1.214: tRNA (guanine10-N2)-methyltransferase EC 2.1.1.215: tRNA (guanine26-N2/guanine27-N2)-dimethyltransferase EC 2.1.1.216: tRNA (guanine26-N2)-dimethyltransferase EC 2.1.1.217: tRNA (adenine22-N1)-methyltransferase EC 2.1.1.218: tRNA (adenine9-N1)-methyltransferase EC 2.1.1.219: tRNA (adenine57-N1/adenine58-N1)-methyltransferase EC 2.1.1.220: tRNA (adenine58-N1)-methyltransferase EC 2.1.1.221: tRNA (guanine9-N1)-methyltransferase EC 2.1.1.222: 2-polyprenyl-6-hydroxyphenyl methylase EC 2.1.1.223: tRNA1Val (adenine937-N6)-methyltransferase EC 2.1.1.224: 23S rRNA (adenine2503-C8)-methyltransferase EC 2.1.1.225: tRNA:m4X modification enzyme EC 2.1.1.226: 23S rRNA (cytidine1920-2′-O)-methyltransferase EC 2.1.1.227: 16S rRNA (cytidine1409-2′-O)-methyltransferase EC 2.1.1.228: tRNA (guanine37-N1)-methyltransferase EC 2.1.1.229: tRNA (carboxymethyluridine34-5-O)-methyltransferase EC 2.1.1.230: 23S rRNA (adenosine1067-2′-O)-methyltransferase EC 2.1.1.231: flavonoid 4′-O-methyltransferase EC 2.1.1.232: naringenin 7-O-methyltransferase EC 2.1.1.233: [phosphatase 2A protein]-leucine-carboxy methyltransferase EC 2.1.1.234: dTDP-3-amino-3,4,6-trideoxy-α-D-glucopyranose N,N-dimethyltransferase EC 2.1.1.235: dTDP-3-amino-3,6-dideoxy-α-D-glucopyranose N,N-dimethyltransferase EC 2.1.1.236: dTDP-3-amino-3,6-dideoxy-α-D-galactopyranose N,N-dimethyltransferase EC 2.1.1.237: mycinamicin III 3′′-O-methyltransferase EC 2.1.1.238: mycinamicin VI 2′′-O-methyltransferaseD EC 2.1.1.239: L-olivosyl-oleandolide 3-O-methyltransferase EC 2.1.1.240: trans-resveratrol di-O-methyltransferase EC 2.1.1.241: 2,4,7-trihydroxy-1,4-benzoxazin-3-one-glucoside 7-O-methyltransferase EC 2.1.1.242: 16S rRNA (guanine1516-N2)-methyltransferase EC 2.1.1.243: 2-ketoarginine methyltransferase EC 2.1.1.244: protein N-terminal methyltransferase EC 2.1.1.245: 5-methyltetrahydrosarcinapterin—corrinoid/iron-sulfur protein Co-methyltransferase EC 2.1.1.246: [methyl-Co(III) methanol-specific corrinoid protein]—coenzyme M methyltransferase EC 2.1.1.247: (methyl-Co(III) methylamine-specific corrinoid protein)—coenzyme M methyltransferase EC 2.1.1.248: methylamine—corrinoid protein Co-methyltransferase EC 2.1.1.249: dimethylamine—corrinoid protein Co-methyltransferase EC 2.1.1.250: trimethylamine—corrinoid protein Co-methyltransferase EC 2.1.1.251: methylated-thiol—coenzyme M methyltransferase EC 2.1.1.252: tetramethylammonium—corrinoid protein Co-methyltransferase EC 2.1.1.253: [methyl-Co(III) tetramethylammonium-specific corrinoid protein]—coenzyme M methyltransferase EC 2.1.1.254: erythromycin 3′′-O-methyltransferase EC 2.1.1.255: geranyl diphosphate 2-C-methyltransferase EC 2.1.1.256: tRNA (guanine6-N6-methyltransferase) EC 2.1.1.257: tRNA (pseudouridine54-N1)-methyltransferase EC 2.1.1.258: 5-methyltetrahydrofolate—corrinoid/iron-sulfur protein Co-methyltransferase EC 2.1.1.259: [fructose-bisphosphate aldolase]-lysine N-methyltransferase EC 2.1.1.260: rRNA small subunit pseudouridine methyltransferase Nep1 EC 2.1.1.261: 4-dimethylallyltryptophan N-methyltransferase EC 2.1.1.262: squalene methyltransferase EC 2.1.1.263: botryococcene C-methyltransferase EC 2.1.1.264: 23S rRNA (guanine2069-N7)-methyltransferase EC 2.1.1.265: tellurite methyltransferase EC 2.1.1.266: 23S rRNA (adenine2030-N6)-methyltransferase EC 2.1.1.267: flavonoid 3′,5′-methyltransferase EC 2.1.1.268: tRNAThr (cytosine32-N3)-methyltransferase EC 2.1.1.269: dimethylsulfoniopropionate demethylase EC 2.1.1.270: (+)-6a-hydroxymaackiain 3-O-methyltransferase EC 2.1.1.271: cobalt-precorrin-4 methyltransferase EC 2.1.1.272: cobalt-factor III methyltransferase EC 2.1.1.273: benzoate O-methyltransferase EC 2.1.1.274: salicylate 1-O-methyltransferase EC 2.1.1.275: gibberellin A9 O-methyltransferase EC 2.1.1.276: gibberellin A4 carboxyl methyltransferase EC 2.1.1.277: anthranilate O-methyltransferase EC 2.1.1.278: indole-3-acetate O-methyltransferase EC 2.1.1.279: trans-anol O-methyltransferase EC 2.1.1.280: selenocysteine Se-methyltransferase EC 2.1.1.281: phenylpyruvate C3-methyltransferase EC 2.1.1.282: tRNAPhe 7-[(3-amino-3-carboxypropyl)-4-demethylwyosine37-N4]-methyltransferase EC 2.1.1.283: emodin O-methyltransferase EC 2.1.1.284: 8-demethylnovobiocic acid C8-methyltransferase EC 2.1.1.285: demethyldecarbamoylnovobiocin O-methyltransferase EC 2.1.1.286: 25S rRNA (adenine2142-N1)-methyltransferase EC 2.1.1.287: 25S rRNA (adenine645-N1)-methyltransferase EC 2.1.1.288: aklanonic acid methyltransferase EC 2.1.1.289: cobalt-precorrin-7 (C5)-methyltransferase EC 2.1.1.290: tRNAPhe [7-(3-amino-3-carboxypropyl)wyosine37-O]-methyltransferase EC 2.1.1.291: (R,S)-reticuline 7-O-methyltransferase EC 2.1.1.292: carminomycin 4-O-methyltransferase EC 2.1.1.293: 6-hydroxytryprostatin B O-methyltransferase EC 2.1.1.294: 3-O-phospho-polymannosyl GlcNAc-diphospho-ditrans,octacis-undecaprenol 3-phospho-methyltransferase EC 2.1.1.295: 2-methyl-6-phytyl-1,4-hydroquinone methyltransferase EC 2.1.1.296: methyltransferase cap2 EC 2.1.1.297: peptide chain release factor N5-glutamine methyltransferase EC 2.1.1.298: ribosomal protein L3 N5-glutamine methyltransferase EC 2.1.1.299: protein N-terminal monomethyltransferase EC 2.1.1.300: pavine N-methyltransferase EC 2.1.1.301: cypemycin N-terminal methyltransferase EC 2.1.1.302: 3-hydroxy-5-methyl-1-naphthoate 3-O-methyltransferase EC 2.1.1.303: 2,7-dihydroxy-5-methyl-1-naphthoate 7-O-methyltransferase EC 2.1.1.304: L-tyrosine C3-methyltransferase EC 2.1.1.305: 8-demethyl-8-α-L-rhamnosyltetracenomycin-C 2′-O-methyltransferase EC 2.1.1.306: 8-demethyl-8-(2-methoxy-α-L-rhamnosyl)tetracenomycin-C 3′-O-methyltransferase EC 2.1.1.307: 8-demethyl-8-(2,3-dimethoxy-α-L-rhamnosyl)tetracenomycin-C 4′-O-methyltransferase EC 2.1.1.308: cytidylyl-2-hydroxyethylphosphonate methyltransferase EC 2.1.1.309: 18S rRNA (guanine1575-N7)-methyltransferase EC 2.1.1.310: 25S rRNA (cytosine2870-C5)-methyltransferase EC 2.1.1.311: 25S rRNA (cytosine2278-C5)-methyltransferase EC 2.1.1.312: 25S rRNA (uracil2843-N3)-methyltransferase EC 2.1.1.313: 25S rRNA (uracil2634-N3)-methyltransferase EC 2.1.1.314: diphthine methyl ester synthase EC 2.1.1.315: 27-O-demethylrifamycin SV methyltransferase EC 2.1.1.316: mitomycin 6-O-methyltransferase EC 2.1.1.317: sphingolipid C9-methyltransferase EC 2.1.1.318: [trehalose-6-phosphate synthase]-L-cysteine S-methyltransferase EC 2.1.1.319: type I protein arginine methyltransferase EC 2.1.1.320: type II protein arginine methyltransferase EC 2.1.1.321: type III protein arginine methyltransferase EC 2.1.1.322: type IV protein arginine methyltransferase EC 2.1.1.323: (–)-pluviatolide 4-O-methyltransferase EC 2.1.1.324: dTDP-4-amino-2,3,4,6-tetradeoxy-D-glucose N,N-dimethyltransferase EC 2.1.1.325: juvenile hormone-III synthase EC 2.1.1.326: N-acetyldemethylphosphinothricin P-methyltransferase EC 2.1.1.327: phenazine-1-carboxylate N-methyltransferase EC 2.1.1.328: N-demethylindolmycin N-methyltransferase EC 2.1.1.329: demethylphylloquinol methyltransferase EC 2.1.1.330: 5′-demethylyatein 5′-O-methyltransferase EC 2.1.1.331: bacteriochlorophyllide d C-121-methyltransferase EC 2.1.1.332: bacteriochlorophyllide d C-82-methyltransferase EC 2.1.1.333: bacteriochlorophyllide d C-20 methyltransferase EC 2.1.1.334: methanethiol S-methyltransferase EC 2.1.1.335: 4-amino-anhydrotetracycline N4-methyltransferase EC 2.1.1.336: norbelladine O-methyltransferase EC 2.1.1.337: reticuline N-methyltransferase EC 2.1.1.338: desmethylxanthohumol 6′-O-methyltransferase EC 2.1.1.339: xanthohumol 4-O-methyltransferase EC 2.1.1.340: 3-aminomethylindole N'-methyltransferase EC 2.1.1.341: vanillate/3-O-methylgallate O-demethylase EC 2.1.1.342: anaerobilin synthase EC 2.1.1.343: 8-amino-8-demethylriboflavin N,N-dimethyltransferase EC 2.1.1.344: ornithine lipid N-methyltransferase EC 2.1.1.345: psilocybin synthase EC 2.1.1.346: U6 snRNA m6A methyltransferase EC 2.1.1.347: (+)-O-methylkolavelool synthase EC 2.1.1.348: mRNA m6A methyltransferase EC 2.1.1.349: toxoflavin synthase EC 2.1.1.350: menaquinone C8-methyltransferase EC 2.1.1.351: nocamycin O-methyltransferase EC 2.1.1.352: 3-O-acetyl-4′-O-demethylpapaveroxine 4′-O-methyltransferase EC 2.1.1.353: demethylluteothin O-methyltransferase EC 2.1.1.354: [histone H3]-lysine4 N-trimethyltransferase EC 2.1.1.355: [histone H3]-lysine9 N-trimethyltransferase EC 2.1.1.356: [histone H3]-lysine27 N-trimethyltransferase EC 2.1.1.357: [histone H3]-lysine36 N-dimethyltransferase EC 2.1.1.358: [histone H3]-dimethyl-L-lysine36 N-methyltransferase. Now known to have the activity of EC 2.1.1.359, [histone H3]-lysine36 N-trimethyltransferase. EC 2.1.1.359: [histone H3]-lysine36 N-trimethyltransferase EC 2.1.1.360: [histone H3]-lysine79 N-trimethyltransferase EC 2.1.1.361: [histone H4]-lysine20 N-methyltransferase EC 2.1.1.362: [histone H4]-N-methyl-L-lysine20 N-methyltransferase EC 2.1.1.363: pre-sodorifen synthase EC 2.1.1.364: [histone H3]-lysine4 N-methyltransferase EC 2.1.1.365: MMP 1-O-methyltransferase EC 2.1.1.366: [histone H3]-N6,N6-dimethyl-lysine9 N-methyltransferase EC 2.1.1.367: [histone H3]-lysine9 N-methyltransferase EC 2.1.1.368: [histone H3]-lysine9 N-dimethyltransferase EC 2.1.1.369: [histone H3]-lysine27 N-methyltransferase EC 2.1.1.370: [histone H3]-lysine4 N-dimethyltransferase EC 2.1.1.371: [histone H3]-lysine27 N-dimethyltransferase EC 2.1.1.372: [histone H4]-lysine20 N-trimethyltransferase EC 2.1.1.373: 2-hydroxy-4-(methylsulfanyl)butanoate S-methyltransferase EC 2.1.1.374: 2-heptyl-1-hydroxyquinolin-4(1H)-one methyltransferase EC 2.1.1.375: NNS virus cap methyltransferase EC 2.1.1.376: glycine betaine—corrinoid protein Co-methyltransferase EC 2.1.1.377: [methyl-Co(III) glycine betaine-specific corrinoid protein]—coenzyme M methyltransferase EC 2.1.1.378: [methyl-Co(III) glycine betaine-specific corrinoid protein]—tetrahydrofolate methyltransferase EC 2.1.1.379: [methyl coenzyme M reductase]-L-arginine C-5-methyltransferase
== Interactions == Surfactant protein D has been shown to interact with DMBT1, and hemagglutinin of influenza A virus. Post-translational modification of SP-D i.e. S-nitrosylation switches its function.
Sources: en.wikipedia.org
Russian forces captured the village of Tymofiivka in Donetsk Oblast. Russia launched a massive drone attack on Kyiv, with Ukrainian forces claiming to have intercepted 40 drones. Russian forces claimed to have intercepted a Neptune-MD missile and 19 drones over Belgorod, Bryansk, Kursk, Kaluga, and Rostov Oblasts as well as in Crimea. The acting governor of Kursk, Alexei Smirnov, said that an “unidentified facility” caught fire after midnight. Ukraine claimed it was a “storage facility for weapons and military equipment”. In Belgorod, commercial and residential properties caught fire. No casualties were reported in the attacks. The Belgorod governor also claimed Ukrainian forces fired six cluster shells at buildings. The Freedom of Russia Legion announced its withdrawal from the Irpin Declaration, but said that it would continue to fight Kremlin forces. A Russian Mi-8 helicopter was shot down over occupied Donetsk, speculated to be either by a Ukrainian FPV drone or by Russian fire. Ukraine received its first F-16s. Austrian military analyst Col. Markus Reisner, citing a recent military study, estimated that Russian forces had lost between 500,000 and 750,000 soldiers killed and wounded in action, with "perhaps" 100,000 to 150,000 Russian soldiers killed. He also said that Ukraine had "suffered very heavy losses".
This is in part due to the myriad job titles used to describe them, including clinical physiologists, medical physicists, and clinical biochemists, which generally mean the public and other healthcare workers assume clinical scientists to be medically qualified doctors, due to the sometimes complex nature of the role.
There are several medication-assisted treatments available for people with opioid use disorder or opioid dependence who are at higher risk for opioid overdose. The selection of treatment depends on various factors, such as a person's preference, accessibility, and history of treatment. Examples of medication-assisted treatments are buprenorphine (with or without naloxone), naltrexone, and methadone. Methadone and buprenorphine are associated with reduced mortality in those with opioid use disorder as well as higher drug treatment program retention, lower illicit drug use, and decreased overdose deaths. The mortality benefit of long-term naltrexone use in those with opioid use disorder is less well-established. After a non-fatal opioid overdose, subsequent methadone or buprenorphine initiation and use reduce the risk of overdose death by 59% and 38%, respectively. Initiating buprenorphine in the emergency department is associated with lower mortality and increased adherence to opioid use disorder treatment programs. Peer support groups have tentative evidence of benefit. There is also some evidence indicating benefits in community-based overdose education and naloxone distribution programs. Buprenorphine and methadone can help decrease drug cravings. Combining pharmacologic treatments with behavioral therapy, such as support or recovery groups, can increase the likelihood of overcoming addiction and reduce the risk of an opioid overdose.
Increased probability of cell mutation (carcinogenic activity) A multitude of simultaneous assorted actions which may be deleterious Interaction (additive, multiplicative, or metabolic) Induced physiological damage, or abnormal chronic conditions Overstimulation or Inhibition of receptors- lead to harmful physiological changes Development of tolerance - reduce their responsiveness, requiring higher doses of drug. Induced pathological conditions - long term structural or functional changes Disturbed homeostasis Functional selectivity (biased Agonism) - preferentially activate certain pathways over others, potentially leading to off-target or unanticipated effects.
=== Road salt === When plants are exposed to increasing concentrations of road salt, the plant cells become dysfunctional and undergo apoptosis, leading to inhibited growth. Inositol pretreatment could reduce these effects.
Sources: en.wikipedia.org
== Causes == Polymyositis is an inflammatory myopathy mediated by cytotoxic T cells with an as yet unknown autoantigen, while dermatomyositis is a humorally mediated angiopathy resulting in myositis and a typical dermatitis. The cause of polymyositis is unknown and may involve viruses and autoimmune factors. Cancer may trigger polymyositis and dermatomyositis, possibly through an immune reaction against cancer that also attacks a component of muscles. There is tentative evidence of an association with celiac disease.
== Pediatric dialysis == Over the past 20 years, children have benefited from major improvements in both technology and clinical management of dialysis. Morbidity during dialysis sessions has decreased with seizures being exceptional and hypotensive episodes rare. Pain and discomfort have been reduced with the use of chronic internal jugular venous catheters and anesthetic creams for fistula puncture. Non-invasive technologies to assess patient target dry weight and access flow can significantly reduce patient morbidity and health care costs. Mortality in paediatric and young adult patients on chronic hemodialysis is associated with multifactorial markers of nutrition, inflammation, anaemia and dialysis dose, which highlights the importance of multimodal intervention strategies besides adequate hemodialysis treatment as determined by Kt/V alone. Biocompatible synthetic membranes, specific small size material dialyzers and new low extra-corporeal volume tubing have been developed for young infants. Arterial and venous tubing length is made of minimum length and diameter, a <80 ml to <110 ml volume tubing is designed for pediatric patients and a >130 to <224 ml tubing are for adult patients, regardless of blood pump segment size, which can be of 6.4 mm for normal dialysis or 8.0mm for high flux dialysis in all patients. All dialysis machine manufacturers design their machine to do the pediatric dialysis.
The new 37th district is based in all but the westernmost parts of Austin, with virtually all of the precincts of the exclusively Travis County-based district favoring Democrats to varying degrees; the new district has a White plurality with a 34% Hispanic voting age population. The incumbent is Democrat Lloyd Doggett, who was re-elected with 75.9% of the vote in 2024. On August 21, 2025, Doggett announced that he would not seek re-election due to mid-decade redistricting, and fellow Democratic Rep. Greg Casar being moved into the 37th district. On August 25, 2025, Casar announced his bid for re-election from this district. Kamala Harris won 76.8% of the vote in the new 37th District, which also gave 79.2% of the vote to Colin Allred; in both cases, the highest of any district amongst the state's new congressional districts.
==== Taxation of e-commerce ==== In early 2023 the government announced plans to remove tax exemptions for international purchases up to US$50 between individuals. After negative reactions the government maintained the rule, but later introduced the “Remessa Conforme” program in August 2023.
=== Uncompetitive === In uncompetitive inhibition the inhibitor binds only to the enzyme-substrate complex. This type of inhibition causes Vmax to decrease (maximum velocity decreases as a result of removing activated complex) and Km to decrease (due to better binding efficiency as a result of Le Chatelier's principle and the effective elimination of the ES complex thus decreasing the Km which indicates a higher binding affinity). Uncompetitive inhibition is rare.
Sources: en.wikipedia.org
No. Epithalamin is a heterogeneous peptide fraction obtained from pineal gland extract and contains many components. Epitalon is a single synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. Researchers synthesised the shorter peptide while attempting to identify active sequences within the extract.
No endogenous peptide with this exact sequence has been described as a circulating hormone or signalling molecule. The tetrapeptide was designed as a synthetic analogue based on fragments observed in pineal preparations. Any activity discussed in the literature therefore refers to administered material rather than to a natural pool of the compound.
It is not an approved medicine in major jurisdictions and does not appear in the major pharmacopoeias. Material is usually distributed as a research chemical or laboratory reagent. Such labelling places handling responsibility on the purchaser and does not indicate that a regulatory body has reviewed the substance.
Epitalon is a synthetic tetrapeptide built from four amino acids: alanine, glutamate, aspartate, and glycine. It is not extracted from a natural source but made in the laboratory by chemical synthesis. Its short length makes it relatively straightforward to produce at high purity.